| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
L-161240 targets the enzyme LpxC, a deacetylase that is essential for the biosynthesis of lipid A, the hydrophobic anchor of lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria. LpxC catalyzes the deacetylation of UDP-3-O-acyl-N-acetylglucosamine, a critical step in the lipid A biosynthetic pathway. By inhibiting LpxC with a Ki of 50 nM, L-161240 blocks the production of lipid A, thereby disrupting the integrity of the bacterial outer membrane and leading to cell death.
|
|---|---|
| ln Vitro |
In vitro, L-161240 is a potent inhibitor of LpxC with a Ki of 50 nM and an IC₅₀ of 30 nM. It exhibits antibacterial activity against wild-type E. coli with a MIC value of 1-3 μg/mL. These in vitro activities confirm its mechanism as an LpxC inhibitor and its potent antibacterial effects.
|
| ln Vivo |
Detailed in vivo activity data for L-161240 are not extensively reported in the available literature. However, as a potent inhibitor of LpxC with antibacterial activity against E. coli, it is expected to have in vivo efficacy in models of Gram-negative bacterial infections. Further in vivo studies would be required to fully characterize its therapeutic potential.
|
| Enzyme Assay |
Non-cell-based enzyme assays for L-161240 typically involve in vitro LpxC activity assays using purified recombinant LpxC enzyme. The compound is incubated with the enzyme and a substrate at varying concentrations. LpxC activity is measured by quantifying the deacetylation of the substrate using HPLC or colorimetric methods. The Ki of 50 nM and IC₅₀ of 30 nM are determined from dose-response curves.
|
| Cell Assay |
Cellular assays for L-161240 are performed using bacterial cultures, such as wild-type E. coli. Bacteria are grown in appropriate medium and treated with the compound at various concentrations. The minimum inhibitory concentration (MIC) is determined using broth microdilution or agar dilution methods, with a reported MIC of 1-3 μg/mL.
|
| Animal Protocol |
In vivo animal models for L-161240 would be required to assess its therapeutic potential. Based on its mechanism as an LpxC inhibitor with activity against E. coli, relevant models could include mouse models of E. coli infection, such as sepsis or urinary tract infection models. The compound would be administered via appropriate routes at various doses. Efficacy would be assessed by measuring bacterial burden and survival.
|
| ADME/Pharmacokinetics |
L-161240 has a molecular weight of 308.33 g/mol and a molecular formula of C₁₅H₂₀N₂O₅. Its CAS number is 183298-68-2. The compound is supplied as a solid with a purity of >99%. It is soluble in DMSO. Storage conditions: -20°C. The compound is an antimicrobial agent targeting lipid A biosynthesis. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for L-161240 are not extensively reported in the available literature. As a research compound, its safety profile would need to be established through standard preclinical toxicity assessments. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
L-161240 is an antimicrobial agent that inhibits lipid A biosynthesis. It targets the enzyme LpxC with a Ki of 50 nM and an IC₅₀ of 30 nM. It exhibits antibacterial activity against wild-type E. coli with a MIC of 1-3 μg/mL. L-161240 is used in research on bacterial infections and antimicrobial drug discovery. Its CAS number is 183298-68-2.
|
| Molecular Formula |
C15H20N2O5
|
|---|---|
| Molecular Weight |
308.3297
|
| Exact Mass |
308.137
|
| CAS # |
183298-68-2
|
| PubChem CID |
9839581
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
415
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC1=C(C(=CC(=C1)C2=N[C@H](CO2)C(=O)NO)OC)OC
|
| InChi Key |
DGGKRIGJIQRXQD-LLVKDONJSA-N
|
| InChi Code |
InChI=1S/C15H20N2O5/c1-4-5-9-6-10(7-12(20-2)13(9)21-3)15-16-11(8-22-15)14(18)17-19/h6-7,11,19H,4-5,8H2,1-3H3,(H,17,18)/t11-/m1/s1
|
| Chemical Name |
(4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2433 mL | 16.2164 mL | 32.4328 mL | |
| 5 mM | 0.6487 mL | 3.2433 mL | 6.4866 mL | |
| 10 mM | 0.3243 mL | 1.6216 mL | 3.2433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
